Regeneron Pharmaceuticals Inc. (REGN) shares surged 5.9% in after-hours on Friday, November 05, 2021, and closed the weekly trading at $647.63. However, in the regular trading session, REGN’s stock lost 5.57%. REGN shares have risen 3.86% over the last 12 months, and they have moved down 4.44% in the past week. Over the past three months, the stock has lost 0.39%, while over the past six months, it has soared 21.74%.
Let’s have a brief discussion about its recent news.
REGN participation at the upcoming ASH annual meeting
On November 4, 2021, Regeneron Pharmaceuticals, Inc. (REGN) announced that new and updated data from its diverse hematology program in blood cancers and disorders will be presented at the 2021 American Society of Hematology (ASH) Annual Meeting from December 11-14 in Atlanta, GA.
REGN recent financial results announcement
On November 04, 2021, Regeneron Pharmaceuticals, Inc. (REGN) announced financial results for the third quarter of 2021.
Q3 2021 financial highlights
- REGN reported total revenue of $3.453 billion in the third quarter of 2021, compared to $2.294 billion in the third quarter of 2020.
- Total cost and expenses were $1.60 billion in Q3 2021 compared to $1.24 billion in Q3 2020.
- It earned net income of $1.632 billion in Q3 2021 or net income per diluted share of $14.33 in Q3 2021 compared to net income of $842.1 million or net income per diluted share of $7.39 in the third quarter of 2020.
REGN Dupixent phase 3 trial results
On October 25, 2021, Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi announced results from a second Phase 3 trial assessing the investigational (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE). The trial met its co-primary endpoints in patients taking Dupixent 300 mg weekly, showing significant improvements in clinical (Dysphagia Symptom Questionnaire) and histologic disease measures compared to placebo. In September 2020, the U.S. Food and Drug Administration the treatment of patients 12 years and older with EoE.
FDA Expands Approval of REGN Dupixent (dupilumab)
On October 20, 2021, Food and Drug Administration (FDA) approved REGN dupilumab as an add-on maintenance treatment of patients aged 6 to 11 years with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.
FDA accepted REGN BLA for REGEN-COV
On October 14, 2021, FDA accepted Regeneron Pharmaceuticals, Inc. (REGN) priority review a Biologics License Application (BLA) for REGEN-COV® (casirivimab and imdevimab) to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals. A target action date of April 13, 2022, is assigned by the FDA.
Conclusion
There is no news for Friday, but its early loss was connected to the financial results announcement of November 4. But we had no reason to justify its gains in the after-hours on Friday.
